Clin2Atlas
AtlasBrain & nervesNeurological disorders

Multiple sclerosis

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251993 — Interferon beta-1b approved (FDA)1993 — Cladribine approved (FDA)1996 — Glatiramer acetate approved (FDA)1996 — Interferon beta-1a approved (FDA)1997 — Daclizumab approved (FDA)2001 — Alemtuzumab approved (FDA)2004 — Mycophenolic acid approved (FDA)2004 — Natalizumab approved (FDA)2009 — Ofatumumab approved (FDA)2010 — Fingolimod approved (FDA)2010 — Dalfampridine approved (FDA)2012 — Teriflunomide approved (FDA)2013 — Dimethyl fumarate approved (FDA)2014 — Peginterferon beta-1a approved (FDA)2017 — Ocrelizumab approved (FDA)2019 — Diroximel fumarate approved (FDA)2019 — Siponimod approved (FDA)2020 — Ozanimod approved (FDA)2020 — Monomethyl fumarate approved (FDA)2021 — Ponesimod approved (FDA)2022 — Ublituximab approved (FDA)
1993: Drug approval — Interferon beta-1b approved (FDA). 1993: Drug approval — Cladribine approved (FDA). 1996: Drug approval — Glatiramer acetate approved (FDA). 1996: Drug approval — Interferon beta-1a approved (FDA). 1997: Drug approval — Daclizumab approved (FDA). 2001: Drug approval — Alemtuzumab approved (FDA). 2004: Drug approval — Mycophenolic acid approved (FDA). 2004: Drug approval — Natalizumab approved (FDA). 2009: Drug approval — Ofatumumab approved (FDA). 2010: Drug approval — Fingolimod approved (FDA). 2010: Drug approval — Dalfampridine approved (FDA). 2012: Drug approval — Teriflunomide approved (FDA). 2013: Drug approval — Dimethyl fumarate approved (FDA). 2014: Drug approval — Peginterferon beta-1a approved (FDA). 2017: Drug approval — Ocrelizumab approved (FDA). 2019: Drug approval — Diroximel fumarate approved (FDA). 2019: Drug approval — Siponimod approved (FDA). 2020: Drug approval — Ozanimod approved (FDA). 2020: Drug approval — Monomethyl fumarate approved (FDA). 2021: Drug approval — Ponesimod approved (FDA). 2022: Drug approval — Ublituximab approved (FDA)

What's being tested now

2002: 1 trials started2003: 1 trials started2007: 1 trials started2008: 1 trials started2009: 1 trials started2012: 4 trials started2013: 3 trials started2014: 2 trials started2015: 1 trials started2016: 10 trials started2017: 13 trials started2018: 10 trials started2019: 17 trials started2020: 22 trials started2021: 33 trials started2022: 31 trials started2023: 70 trials started2024: 122 trials started2025: 157 trials started2026: 185 trials started201020202026185

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 632 active Multiple sclerosis trials on Clin2 →

Related

Alzheimer's disease and other dementiasParkinson's diseaseIdiopathic epilepsyMotor neuron diseaseOther neurological disorders

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.